IRIDEX (NASDAQ:IRIX) Issues Quarterly Earnings Results, Meets Estimates

IRIDEX (NASDAQ:IRIX) released its quarterly earnings data on Thursday. The medical equipment provider reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05), Zacks reports. The firm had revenue of $12.70 million during the quarter, compared to the consensus estimate of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

IRIDEX Stock Down 1.8 %

Shares of IRIDEX stock opened at $0.88 on Friday. The stock has a market capitalization of $14.69 million, a price-to-earnings ratio of -1.32 and a beta of 0.94. IRIDEX has a twelve month low of $0.78 and a twelve month high of $3.65. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The business’s 50 day simple moving average is $1.38 and its 200-day simple moving average is $1.59.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of IRIDEX in a report on Tuesday. They issued a “hold” rating for the company.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.